| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | -267.3MM | -296% |
| Gross Profit | -136.9MM | -270% |
| Cost Of Revenue | -130.4MM | -331% |
| Operating Income | -43.6MM | -197% |
| Operating Expenses | -93.3MM | -364% |
| Net Income | 15.7MM | -24% |
| R&D | - | - |
| G&A | -93.3MM | -364% |
| Amortization | - | - |
| Interest Expense | -44.8MM | -316% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 (the “Notes”) (CUSIP No. 19459JAA2; ISIN No. US19459JAA25) for redemption on Friday, June 14, 2024 (the “Re
Collegium Pharmaceutical (COLL) closed at $38.79 in the latest trading session, marking a -1.6% move from the prior day.
STOUGHTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference being held virtually from April 8-11, 2024. Details of the event are as follows:Fireside Chat Date and Time: Wednesday, April 10, 2024, at 3:45
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron have been highlighted in this Screen of The Week article.
Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Collegium Pharmaceutical (COLL) could produce exceptional returns because of its solid growth attributes.
Does Collegium Pharmaceutical (COLL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.